US Regulators Clear GE Healthcare's $580M Purchase of Clarient | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Federal Trade Commission has cleared the way for GE Healthcare's purchase of molecular diagnostics and imaging firm Clarient.

The FTC this week granted GE Healthcare early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, removing antitrust barriers in the US to the cash deal, estimated at $570 million to $580 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.